Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of LTB-SA7 Vaccine in Healthy Adults
NCT06719219Phase 1Completed
- Sponsor
- LimmaTech Biologics
- Start
- Jan 2025
- Primary completion
- Mar 2026
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LBT-SA7 in Staphylococcus aureus infection (7 arms), sponsored by LimmaTech Biologics. Primary endpoints: Solicited local and systemic Adverse Events at 7 days, Unsolicited Adverse Events at 28 days and 2 more. Started Jan 2025; status: completed.
02
Drugs
LBT-SA7
03
Conditions
Staphylococcus aureus infection
Beyond the preview
Go deeper on NCT06719219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06719219.